PRACTICAL ONCOLOGY JOURNAL ›› 2012, Vol. 26 ›› Issue (1): 92-96.doi: 10.3969/j.issn.1002-3070.2012.01.019
Previous Articles
YANG Fang,WANG Meng,YANG Zhaoyang,HONG Xuan,CHEN Gongyan
Received:
Online:
Published:
Abstract: Objective The aim of this study is to explore the prognostic factors of advanced NSCLC patients treated with erlotinib.Methods Clinical characteristics of fifty-five advanced NSCLC patients treated with erlotinib were collected.The association of their clinical characteristics with median progression-free survival time(PFS)and overall survival(OS)was analysed.Results High serum LDH level and grade 0-1 rash were independent risk factors for bad prognostic in patients.Conclusion Serum LDH level and grade of rash are important prognostic factors in advanced Non-small Cell Lung Cancer treated with erlotinib.
Key words: Erlotinib, Advanced Non-small Cell Lung Cancer, Prognostic factor
CLC Number:
R734.2
YANG Fang,WANG Meng,YANG Zhaoyang,HONG Xuan,CHEN Gongyan. Explore the Prognostic Factors of Advanced NSCLC Patients Treated with Erlotinib[J]. PRACTICAL ONCOLOGY JOURNAL, 2012, 26(1): 92-96.
0 / / Recommend
Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks
URL: http://www.syzlxzz.com/EN/10.3969/j.issn.1002-3070.2012.01.019
http://www.syzlxzz.com/EN/Y2012/V26/I1/92
